Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)

Leukemia and Lymphoma - United Kingdom
doi 10.3109/10428194.2014.938333
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

Cancer
Cancer ResearchOncology
2010English

Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma

American Journal of Hematology
Hematology
2017English

The Immunologic Doublet of Lenalidomide Plus Obinutuzumab Is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/Ii Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2018English

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Cancer
Cancer ResearchOncology
2016English

Obinutuzumab Plus Ibrutinib in Relapse/Refractory Mantle Cell Lymphoma Patients: First Results of the Oasis Phase I Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy